Abstract
Eniluracil (5-ethynyluracil, GW 776, 776C85) isbeing developed as a novel modulator of 5-fluorouracil (5-FU) forthe treatment of cancer. Eniluracil is an effective mechanism-based inactivator of dihydropyrimidine dehydrogenase (DPD), thefirst enzyme in the catabolic pathway of 5-FU. By temporarilyeliminating this prevalent enzyme, eniluracil providespredictable dosing of 5-FU and enables oral administration of5-FU to replace intravenous bolus and continuously infuseddosing. New DPD is synthesized with a half-life of 2.6 days. Italso eliminates the formation of problematic 5-FU catabolites.Most importantly, in laboratory animals, eniluracil increases thetherapeutic index and absolute efficacy of 5-FU. Accompanyingreports in this journal indicate that eniluracil has promisingclinical potential.
Similar content being viewed by others
References
Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39: 34–40, 1977
Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B: Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249–1264, 1987
Chabner, BA, Meyers CE: Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Jr, Hellman S, Rosenberg SA, (eds) Cancer, Principles and Practice of Oncology, 2nd Ed, pp 287–328 Philadelphia, PA: JB Lippincott Co, 1985
Meyers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev 33: 1–15, 1981
Dasher GC, Harris BE, Diasio RB: Metabolism of pyrimidine analogues and their nucleosides. Pharmac Ther 48: 189–222, 1990
Fleming RA, Milano G, Thyss A, Etienne MC, Rence N, Schneider M, Demard F: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899–2902, 1992
Grem X, Yee LK, Venzon DJ, Takimoto CH, Allegra CJ: Interand intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40: 117–125, 1997
Harris BE, Song R, Soong SJ, Diasio RB: Relationships between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201, 1990
Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1676–1679, 1988
Morrison GB, Bastian A, Dela Rosa T, Diasio RB, Takimoto CH: Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 24: 83–88, 1997
Ho DH, Townsend L, Luna MA, Bodey GP: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781–784, 1986
Naguib FN, el Kouni MH Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405–5412, 1985
Spector T, Harrington JA, Porter DJT: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243–2248, 1993
Christophidis N, Vajda HE, Lucas I, Drummer O, Moon WJ, Louis WJ: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinetics 3: 330–336, 1978
Cohen JL, Irwin LE, Marshall GJ, Darvey H, Bateman JR: Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother Rep 58: 723–731, 1974
Finch RE, Bending MR, Lant AF: Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Phamacol 7: 613–617, 1979
Etienne MC, Cheradame S, Fischel M, Formento P, Dassonville O, Rence N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663–1670, 1995
Fischel JL, Etienne MC, Spector T, Formento P, Renee N, Milano G: Dihydropyrimi dine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991–996, 1995
Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoracetic acid and α-fluoro-β-alanine. Acta Neuropathol 81: 66–73, 1990
Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. Arch Neurol 23: 155–160, 1970
Lemaire L, Malet-Martino MC, Longo S, Martino R, deForni M, Carton M: Fluoroacetaldehyde as a cardiotoxic impurity in fluorouracil (Roche). Lancet 337: 560, 1991
Lemaire L, Malet-Martino MC, deForni M, Martino R, Lasserre B: Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66: 119–127, 1992
Hohneker JA: Clinical development of eniluracil: current status. Oncology (Huntingt) 12: 52–56, 1998
Spector T, Cao S, Rustum YM, Harrington JA, Porter DJT: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55: 1239–1241, 1995
Spector, T: 5-Ethynyluracil (776C85): an inactivator of uracil reductase that potentiates the antitumor activity of 5-fluorouracil. Curr Opin Ther Pat 3: 1751–1754, 1993
Spector T, Porter MT, Nelson DJ, Baccanari DP, Davis ST, Almond MR, Khor SP, Amyx H, Cao S, Rustum YM: 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs of the Future 19: 565–571, 1994
Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil: Effects on the pharmacokinetics, and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci 90: 11064–11068, 1993
Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54: 1507–1510, 1994
Paff MT, De La Mata MA, Nelson DJ: Pharmacokinetics and metabolism of 5-ethynyluracil, an inhibitor of 5-fluorouracil catabolism in male CD-1 mice. (Abstract) Proc Amer ASSOC Cancer Res 35: 321, 1994
Porter WT, Chestnut WG, Merrill BM, Spector T: Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236–5242, 1992
Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA 3rd: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16: 1450–1457, 1998
Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen SJ, Diasio RB: The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 61: 563–573, 1997
McLeod, HL, Ahmed, FY, Johnston SJ, O'Kelly T, Binnie N, Murray GI, van Gennip AR, Knight S, Cassidy J: Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase activity in colorectal tumors. (Abstract) Proc Am Soc Clin Oncol 18: 201a, 1999
Burris HA, Schilsky RL, Fields S, Lucas VS, Khor SP, Spector T, Guaspari A, Smetzer L, Janisch L, Von Hoff DD: Phase I trial of dihydropyrimidine dehydrogenase inactivator 5-ethynyluracil (776C85) plus 5-fluorouracil. (Abstract) Proc Am Soc Clin Oncol 14: 171, 1995
Arellano NI, Malet-Martino NI, Martino R, Spector T: 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid, in the isolated perfused rat liver model. British J Cancer 76: 1170–1180, 1997
Adams ER, Leffert JJ, Craig DJ, Spector T, Pizzorno G: In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F-NMR spectroscopy. Cancer Res 59: 122–127, 1999
Lambe CU, Donnell BB, Shockcor J, Nelson DJ: 5-Fluorouracil catabolism in rats is decreased by 5-ethynyluracil (776C85), an inactivator of uracil reductase. (Abstract) Proc Amer Assoc Cancer Res 36: 363, 1995
Heggie D, Sommadossi JP, Cross DS, Fluster WJ, Diasio R: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203–2206, 1987
Coustere C, Mentre F, Sornmadossi JP, Diasio R, Steimer J-L: A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 28: 123–129, 1991
Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Amin JM, Jersey J, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of 5-fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncology 14: 3085–3096, 1996
Davis ST, Joyner SS, Baccanari DP, Spector T: 5-Ethynyluracil (776C85): protection from 5-fluorouracilinduced neurotoxicity in dogs. Biochem Pharrnacol 48: 233–236, 1994
Schaaf U, Dobbs BR, Edwards IR, Perrier DG: Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol 32: 411–418, 1987
Abernathy DR, Alper JC, Wiemann MC, McDonald CJ, Calabresi P: Oral 5-fluorouracil in psoriasis: pharmacokineticpharmacodynamic relationships. Pharmacol 39: 78–88, 1989
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281, 1998
Mani S, Beck T, Chevlen E, Hochster H, O'Rourke M, Weaver C, Bell W, McGuirt C, Levin J, Holmeker J, Lokich J: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). (Abstract) Proc Am Soc Clin Oncol 17: 281 a, 1998
Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308, 1998
Kamm YJ, Wagener DJ, Rietjens IM, Punt CJ: 5-Fluorouracil in colorectal cancer: rational and clinical results of frequently used schedules. Anticancer Drugs 9: 371–380, 1998
Fischel JL, Formento P, Etienne MC, Spector T, Rence N, Milano G: Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol 53: 1703–1709, 1997
Schilsky RL, Bukowsky R, Burris HA, WoIff R, Hochster H, O'Rourke M, Stienfeld H, Doucette M, Hohneker JA: Phase II study of a five day regimen of oral 5-Fluorouracil (5-FU) plus GW776 (776C85) with and without leucovorin (LV) in patients with metastatic colorectal cancer. (Abstract) Proc Am Soc Clin Oncol: 16: 271a, 1997
Cao S, Baccanari DP, Joyner SS, Davis ST, Rustum M Spector T: 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil, Cancer Res 55: 6227–6230, 1995
Woodcock TM, Martin DS, Damin LAM, Kemeny NE, Young CW: Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacological evaluation. Cancer (Phila) 45: 1135–1143, 1980
Porter DJT, Harrington JA, Almond MR, Lowen GT, Spector T: (R)-5-Fluoro-5,6-dihydrouracil: kinetics of oxidation by dihydropyrimidine dehydrogenase and hydrolysis by dihydropyrimidine aminohydrolase. Biochem Pharmacol 48:775–779, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paff, M.T., Baccanari, D.P., Davis, S.T. et al. Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil. Invest New Drugs 18, 365–371 (2000). https://doi.org/10.1023/A:1006401432488
Issue Date:
DOI: https://doi.org/10.1023/A:1006401432488